Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia

J. Jankovic; C. Hunter; B. Z. Dolimbek; G. S. Dolimbek; C. H. Adler; A. Brashear; C. L. Comella; M. Gordon; D. E. Riley; K. Sethi; C. Singer; M. Stacy; D. Tarsy; M. Z. Atassi

doi:10.1212/01.wnl.0000249308.66959.43

Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia

J. Jankovic
, C. Hunter
, B. Z. Dolimbek
, G. S. Dolimbek
, C. H. Adler
, A. Brashear
, C. L. Comella
, M. Gordon
, D. E. Riley
, K. Sethi
, C. Singer
, M. Stacy
, D. Tarsy
, M. Z. Atassi

JSMBS Office of the Dean

Baylor College of Medicine
Mayo Clinic Arizona
Rush University Medical Center
Northwell Health System
Case Western Reserve University
Augusta University
University of Miami
St. Joseph's Hospital and Medical Center, Phoenix
Beth Israel Deaconess Medical Center

Research output: Contribution to journal › Article › peer-review

89 Scopus citations

Abstract

In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.

Original language	English
Pages (from-to)	2233-2235
Number of pages	3
Journal	Neurology
Volume	67
Issue number	12
DOIs	https://doi.org/10.1212/01.wnl.0000249308.66959.43
State	Published - Dec 2006

Access to Document

10.1212/01.wnl.0000249308.66959.43

Cite this

@article{cf18b20e63f347718cbc3b173cb6d2b0,

title = "Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia",

abstract = "In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.",

author = "J. Jankovic and C. Hunter and Dolimbek, \{B. Z.\} and Dolimbek, \{G. S.\} and Adler, \{C. H.\} and A. Brashear and Comella, \{C. L.\} and M. Gordon and Riley, \{D. E.\} and K. Sethi and C. Singer and M. Stacy and D. Tarsy and Atassi, \{M. Z.\}",

year = "2006",

month = dec,

doi = "10.1212/01.wnl.0000249308.66959.43",

language = "English",

volume = "67",

pages = "2233--2235",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "12",

}

TY - JOUR

T1 - Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia

AU - Jankovic, J.

AU - Hunter, C.

AU - Dolimbek, B. Z.

AU - Dolimbek, G. S.

AU - Adler, C. H.

AU - Brashear, A.

AU - Comella, C. L.

AU - Gordon, M.

AU - Riley, D. E.

AU - Sethi, K.

AU - Singer, C.

AU - Stacy, M.

AU - Tarsy, D.

AU - Atassi, M. Z.

PY - 2006/12

Y1 - 2006/12

N2 - In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.

AB - In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.

UR - https://www.scopus.com/pages/publications/33845939760

U2 - 10.1212/01.wnl.0000249308.66959.43

DO - 10.1212/01.wnl.0000249308.66959.43

M3 - Article

C2 - 17190952

AN - SCOPUS:33845939760

SN - 0028-3878

VL - 67

SP - 2233

EP - 2235

JO - Neurology

JF - Neurology

IS - 12

ER -

Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia

Abstract

Access to Document

Other files and links

Fingerprint

Cite this